Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Alzamend Neuro, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
Alzamend NeuroAI Executive Summary
AI-powered analysis of 8-K filing content
Dr. Ovidiu C. Andronesi, principal investigator for Alzamend Neuro's Phase 1/2A clinical trial, presented findings at the ISMRT Conference on September 29, 2026, demonstrating progress in the company's neurological research and strengthening relationships with medical professionals.
Key Takeaways
Clinical trial data was presented at a major international medical conference, signaling advancement in Alzamend's neurological research program
The presentation by the principal investigator demonstrates the company's research capabilities to the medical and scientific community
1 more takeaway
Filing Overview
What This Means
Alzamend Neuro, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.